1. The Spectrum of Renal "TFEopathies": Flipping the mTOR Switch in Renal Tumorigenesis.
- Author
-
Alesi N, Asrani K, Lotan TL, and Henske EP
- Subjects
- Humans, Animals, Mechanistic Target of Rapamycin Complex 1 metabolism, Birt-Hogg-Dube Syndrome metabolism, Birt-Hogg-Dube Syndrome genetics, Signal Transduction, Carcinogenesis metabolism, Carcinogenesis genetics, Tuberous Sclerosis metabolism, Tuberous Sclerosis genetics, Tuberous Sclerosis pathology, Carcinoma, Renal Cell metabolism, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell pathology, Multiprotein Complexes metabolism, Multiprotein Complexes genetics, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors metabolism, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors genetics, Kidney Neoplasms metabolism, Kidney Neoplasms pathology, Kidney Neoplasms genetics, TOR Serine-Threonine Kinases metabolism
- Abstract
The mammalian target of Rapamycin complex 1 (mTORC1) is a serine/threonine kinase that couples nutrient and growth factor signaling to the cellular control of metabolism and plays a fundamental role in aberrant proliferation in cancer. mTORC1 has previously been considered an "on/off" switch, capable of phosphorylating the entire pool of its substrates when activated. However, recent studies have indicated that mTORC1 may be active toward its canonical substrates, eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and S6 kinase (S6K), involved in mRNA translation and protein synthesis, and inactive toward TFEB and TFE3, transcription factors involved in the regulation of lysosome biogenesis, in several pathological contexts. Among these conditions are Birt-Hogg-Dubé syndrome (BHD) and, recently, tuberous sclerosis complex (TSC). Furthermore, increased TFEB and TFE3 nuclear localization in these syndromes, and in translocation renal cell carcinomas (tRCC), drives mTORC1 activity toward the canonical substrates, through the transcriptional activation of the Rag GTPases, thereby positioning TFEB and TFE3 upstream of mTORC1 activity toward 4EBP1 and S6K. The expanding importance of TFEB and TFE3 in the pathogenesis of these renal diseases warrants a novel clinical grouping that we term "TFEopathies." Currently, there are no therapeutic options directly targeting TFEB and TFE3, which represents a challenging and critically required avenue for cancer research.
- Published
- 2024
- Full Text
- View/download PDF